Matsuda Masaru sold $1.4M of ARQT
Matsuda Masaru (EVP, Chief Legal Officer) sold 41,219 shares of Arcutis Biotherapeutics, Inc. (ARQT) at an average of $34.24 ($31.86–$34.32, $1.41M total) across 2 trades over 2026-11-02 to 2026-11-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale may lead to short‑term price weakness, but the long‑term effect depends on subsequent company performance.
Market read
A modest insider sell that could cause short‑term pressure but is unlikely to move the broader market.
What to watch
The 10b5‑1 plan may have been set before any material news, limiting informational value.
Background
Form 4 filings disclose insider transactions and are primary sources for such events.
Ticker impact
SEC Form 4 shows EVP Matsuda Masaru sold 41,219 shares for $1.41M via a 10b5‑1 plan.
likely downward pressure as the market prices the insider sell.
A C‑suite officer sold a sizable block at $34 per share, indicating possible valuation concerns.
Market effects
Minimal impact on the broader biotech sector.
None
Low
Counterpoint
The sale could be routine execution of a pre‑arranged plan, not a negative signal.
Key entities
- OfficerMatsuda Masaru
EVP, Chief Legal Officer of Arcutis Biotherapeutics.

